Tenapanor, marketed under the brand names Ibsrela and Xphozah, has been approved by the FDA for the treatment of irritable bowel syndrome with constipation (IBS-C) and for lowering phosphorus levels in the blood in adults with kidney disease.
Sobi revealed that the European Commission has approved the Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa) for the treatment and prevention of bleeding episodes and perioperative prophylaxis in patients with haemophilia A.
The U.S. Food and Drug Administration (FDA) approved lefamulin on August 19, 2019, making it the first pleuromutilin antibiotic available for systemic administration in humans.
The FDA first approved upadacitinib on August 16, 2019, for the treatment of moderate to severe rheumatoid arthritis in adults who have not responded well to methotrexate or other similar medications.
Jun 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.